146978-48-5
Chemical Structure
Moxilubant
Synonym(s): CGS 25019C free base
- CAS No.: 146978-48-5
- Formula:C26H37N3O4
- Molecular Weight:455.59
IUPAC Name: 4-((5-(4-carbamimidoylphenoxy)pentyl)oxy)-N,N-diisopropyl-3-methoxybenzamide
InChIKey: VAYJLOGCWOXMAS-UHFFFAOYSA-N
SMILES: CC(C)N(C(C)C)C(C1=CC(OC)=C(OCCCCCOC2=CC=C(C(N)=N)C=C2)C=C1)=O
Biological Activity: Moxilubant (CGS 25019C free base) is an orally active BLT1 antagonist. Moxilubant inhibits LTB4 signaling with a potency of 2-4 nM. Moxilubant blocks LTB4-induced neutrophil functions. Moxilubant inhibits ear edema and neutrophil infiltration in mice. Moxilubant can be used in research related to chronic obstructive pulmonary disease[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Moxilubant | 99.83% | Moxilubant (CGS 25019C free base) is an orally active BLT1 antagonist. Moxilubant inhibits LTB4 signaling with a potency of 2-4 nM. Moxilubant blocks LTB4-induced neutrophil functions. Moxilubant inhibits ear edema and neutrophil infiltration in mice. Moxilubant can be used in research related to chronic obstructive pulmonary disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Moxilubant (Standard) | ≥98% | Moxilubant (CGS 25019C free base) Standard is the analytical standard of Moxilubant (HY-106929). This product is intended for research and analytical applications. Moxilubant (CGS 25019C free base) is an orally active BLT1 antagonist. Moxilubant inhibits LTB4 signaling with a potency of 2-4 nM. Moxilubant blocks LTB4-induced neutrophil functions. Moxilubant inhibits ear edema and neutrophil infiltration in mice. Moxilubant can be used in research related to chronic obstructive pulmonary disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Raychaudhuri A, et al. Effect of CGS 25019C and other LTB4 antagonists in the mouse ear edema and rat neutropenia models. Inflamm Res. 1995 Aug;44 Suppl 2:S141-2. [Content Brief]
- [2]. Bhatt L, et al. Recent advances in clinical development of leukotriene B4 pathway drugs. Semin Immunol. 2017;33:65-73. [Content Brief]
